NCT07188727Completed
Comparative Outcomes of Ulcerative Colitis Patients With Mayo Endoscopic Score 1 and Histologic Activity Versus Mayo Endoscopic Score 2
Refining Clinical Practice in Ulcerative Colitis: The Prognostic Value of Histologic Remission - A Monocentric Retrospective Study
Source: ClinicalTrials.gov · Last updated 23 Sept 2025
Brief summary (registry, in English)
This retrospective study examines patients with ulcerative colitis who initiated advanced therapy for their disease. In clinical practice, patients with only mild inflammation on endoscopy (Mayo Endoscopic Subscore 1, or MES1) often do not undergo treatment optimization or therapy change. We stratified these patients based on histologic findings from biopsy samples and compared them with patients who had greater endoscopic activity (MES2). We evaluated long-term outcomes, including surgery and hospitalization, to determine whether current management strategies for patients with mild endoscopic disease should be reconsidered.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 159 (actual)
- First submitted
- 16 Sept 2025
- Start date
- 1 Sept 2019
- Primary completion date
- 1 May 2025
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Ulcerative colitis
- NCT number
- NCT07188727
What you commit to
- Study type: Observational
- Participants enrolled: 159
- From 1 Sept 2019 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous colonic surgery (eg. Pouch);
- Patients for whom biopsies were not obtained at the time of endoscopic reassessment (conducted after 12 months following the initiation of advanced therapy);
Other illness
- Patients with unclassified colitis or Crohn's disease;
Who the study is looking for
- Confirmed diagnosis of UC (by routine clinical, radiographic, endoscopic and pathologic criteria);
- Patients starting a new advanced treatment for UC (either biologic agents or small molecules);
- Patients with endoscopic MES of 1 or 2 at the endoscopic reassessment (conducted after 12 ± 3 months following the initiation of advanced therapy)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Hospital Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.